Delaware legislation · 153rd General Assembly
Delaware HB429: Biologics/Biosimilars/Step Therapy/Updates
Status: Signed into law, July 23, 2026
AN ACT TO AMEND TITLE 18 OF THE DELAWARE CODE RELATING TO THE STEP THERAPY EXCEPTION PROCESS.
What the bill says
An act to amend title 18 of the delaware code relating to the step therapy exception process.
From the introduced text, May 19, 2026:
AN ACT TO AMEND TITLE 18 OF THE DELAWARE CODE RELATING TO THE STEP THERAPY EXCEPTION PROCESS. Section 1. Amend § 3381, Title 18 of the Delaware Code by making deletions as shown by strike through and insertions as shown by underline as follows: § 3381. Step therapy exception process [For application of this section, see 82 Del. Laws, c. 44, § 3]. (e) This section shall not be construed to prevent any of the following: (1) An insurer, health plan, or utilization review entity from requiring a patient to try an AB-rated generic equivalent prior to providing coverage for the equivalent branded prescription drug. from requiring a patient to try either of the following: a. An AB-rated generic equivalent or an interchangeable biological product as defined in 42 U.S.C. § 262(i)(3) prior to providing coverage for the equivalent branded prescription drug. b. A biosimilar as defined in 42 U.S.C. § 262(i)(2) prior to providing coverage for the brand name prescription reference product drug or drugs. Section 2. Amend § 3591, Title 18 of the Delaware Code by making deletions as shown by strike through and insertions as shown by underline as follows: § 3591. Step therapy exception process [For application of this section, see 82 Del. Laws, c. 44, § 3]. (e) This section shall not be construed to …
Sponsors
- Melissa Minor-Brown (D, 17) · primary sponsor
- Marie Pinkney (D, 13)
- Debra Heffernan (D, 6)
- Kendra Johnson (D, 5)
- Eric Morrison (D, 27)
- Frank Burns (D, 21)
- Kerri Harris (D, 32)
- Alonna Berry (D, 20)
- William Carson (D, 28)
- Larry Lambert (D, 7)
- Melanie Ross Levin (D, 10)
- Rebecca Snyder-Hall (D, 14)
Latest actions
- : Signed by Governor
- : Passed By Senate. Votes: 21 YES
- : Reported Out of Committee (Banking, Business, Insurance & Technology) in Senate with 5 On Its Merits
- : Assigned to Banking, Business, Insurance & Technology Committee in Senate
- : Passed By House. Votes: 38 YES 1 NO 2 ABSENT
- : Reported Out of Committee (Economic Development/Banking/Insurance & Commerce) in House with 3 Favorable, 6 On Its Merits
- : Introduced and Assigned to Economic Development/Banking/Insurance & Commerce Committee in House
Votes
- Passed (3/4) (June 24, 2026): 21 yea, 0 nay, passed
- Passed (3/4) (June 11, 2026): 38 yea, 1 nay, passed
Common questions
- What is HB429?
- HB429 is a bill in the Delaware Legislature (153rd General Assembly): Biologics/Biosimilars/Step Therapy/Updates.
- What does HB429 do?
- In its own words: An act to amend title 18 of the delaware code relating to the step therapy exception process.
- What is the status of HB429?
- Signed into law as of July 23, 2026. Latest action: Signed by Governor (July 23, 2026).
- Who sponsored HB429?
- Melissa Minor-Brown (D, 17), with 11 co-sponsors.
- Where is the official record for HB429?
- On the Delaware Legislature website: https://legis.delaware.gov/BillDetail?LegislationId=143347
Source: official Delaware record. Tracked by Delilah, AI for legislation across all 50 states and Congress.